CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy

Abstract Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malignancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is transfer of natural or engineered tumor-specific T-cells into patients, a so...

Full description

Bibliographic Details
Main Authors: Seyed Mohammad Miri, Elham Tafsiri, William Chi Shing Cho, Amir Ghaemi
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Cancer Cell International
Subjects:
Cancer immunotherapy
CRISPR-Cas
Cas9
TCR T-cell
CAR T-cell
Allogeneic T-cell
Online Access:http://link.springer.com/article/10.1186/s12935-020-01546-8

Internet

http://link.springer.com/article/10.1186/s12935-020-01546-8

Similar Items